Antares Pharma (ATRS) Reports In-Line Q3 EPS

Antares Pharma (NASDAQ: ATRS) reported Q3 EPS of ($0.03), in-line with the analyst estimate of ($0.03). Revenue for the quarter came in at $15.1 million versus the consensus estimate of $13.96 million.

For earnings history and earnings-related data on Antares Pharma (ATRS) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Cerebras Q1 EPS miss sends shares down 9% after-hours
• FedEx (FDX) Tops Q4 EPS by 39c, Beats on Revenue; Offers FY27 EPS Guidance